Introduction
============

Aniridia (OMIM [106210](http://www.ncbi.nlm.nih.gov/omim/106210)) is a panocular disorder characterized by variable degrees of deficiency of the iris tissue. In 70% cases it presents as a familial disorder with autosomal dominant inheritance. The paired box 6 (*PAX6*) gene is the only gene in which causative mutations have been identified \[[@r1],[@r2]\]. Mutations leading to complete absence of the PAX6 protein are responsible for aniridia phenotype whereas milder mutations with protein production are associated with other ocular presentations like corectopia, Reiger anomaly, cataract, glaucoma, etc \[[@r3]-[@r5]\]. Until date, 718 sequence variants of *PAX6* and 321 pathogenic mutations have been recorded \[[@r6]\]. In the present paper we report the finding of a novel *PAX6* mutation in an Indian family with aniridia. We also attempt to correlate the rare occurrence of chorioretinal degeneration in one of the affected individual with the type of mutation.

Methods
=======

Case description
----------------

A family with an affected father and his two affected sons had attended the genetics department of a tertiary care hospital in North India. The family hailed from the local population and had no other similarly affected family member in the previous generations.

The proband was the elder son, who was 21 years at the time of workup. He had complete absence of iris tissue, microcornea, anterior polar cataract, glaucoma, and immature cortical cataract in both eyes. In addition he had chorioretinal degeneration and multiple vitreous opacities in the right eye and retinal pigment epithelium depigmentation changes in the left eye. However his vision was relatively well conserved and he could carry out his daily chores with the aid of corrective glasses. He had undergone corrective surgery for glaucoma in both eyes 4 years ago. His intra-ocular pressure which was 43 mm-45 mm in both eyes was reduced to 14 mm after the surgery.

His younger brother who was 18 years old was legally blind since the age of 8 years. He also had complete absence of iris tissue in both eyes. In addition, he also had bilateral microcornea and opacification of both corneas more on the left side. He had glaucoma in the right eye (Intra-ocular pressure 28 mmHg) and cataract in the left eye. The left eye was diagnosed as having developed phthisis bulbi. These asymmetric eye findings in this patient could be attributed to previous injury to the left eye at the age of 14.

The father was 45 years old and was legally blind. He had progressive visual loss since age of 25 years. On examination, he also had absence of iris tissue in both eyes. He had bilateral corneal opacities and marked thinning of the cornea. He also had optic nerve atrophy in bilateral eyes, probably due to long standing glaucoma but no prior medical records were available. The pedigree is depicted in [Figure 1](#f1){ref-type="fig"}.

![The family pedigree with salient phenotypic features of the three affected members.](mv-v17-1305-f1){#f1}

Mutation analysis
-----------------

Mutation analysis was done at the Department of Research and Development, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok. Mutation screening in 14 exons of *PAX6* was performed using single strand conformation polymorphism (SSCP) followed by direct DNA sequencing. The primers used are as mentioned by Atchaneeyasakul et al. \[[@r7]\] and shown in [Table 1](#t1){ref-type="table"}.

###### Depicting the primers used in the present study for amplification of *PAX6*.

  **Exon**   **5\'→3\'**                **mer**   **Ta (°C)**   **PCR product size (bp)**
  ---------- -------------------------- --------- ------------- ---------------------------
  1F         GTTTGAAAAGGGAACCGTGG       20        61            243
  1R         CGGCTGGAGAGTGAGAGATA       20                       
  2F         GCATAGGTGTGCTGGCTGCAG      21        62            350
  2R         GGAGACCTGTCTGAATATTGC      21                       
  3F         TCAGAGAGCCCATGGACGTA       20        61            193
  3R         CTGTTTGTGGGTTTTGAGCC       20                       
  4F         CCAGGTCCACCTCGGTTGGGA      21        67            208
  4R         TGTGTCCTCCCCTGACCCTC       20                       
  5F         CCTCTTCACTCTGCTCTCTT       20        60            288
  5R         CATAATTAGCATCGTTTACAGTAA   24                       
  5AF        TGAAAGTATCATCATATTTGTAG    23        57            236
  5AR        GGGAAGTGGACAGAAAACCACA     22                       
  6F         GTGGTTTTCTGTCCACTTCC       20        60            299
  6R         AGGAGAGAGCATTGGGCTTA       20                       
  7F         CAGGAGACACTACCATTTGG       20        60            252
  7R         ATGCACATATGGAGAGCTGC       20                       
  8F         GGGAATGTTTTGGTGAGGCT       20        60            371
  8R         CAAAGGGCCCTGGCTAAATT       20                       
  9F         ACAGTTTGGTCAACATATTTTG     22        60            217
  9R         CAAGCACCTCTGTCTCTAGG       20                       
  10F        GTAGACACAGTGCTAACCTG       20        60            243
  10R        CCCGGAGCAAACAGGTTTAA       20                       
  11F        TTAAACCTGTTTGCTCCGGG       20        63            240
  11R        CCCTGAGCCACTCCTCAC         18                       
  12F        GCTGTGTGATGTGTTCCTCA       20        63            228
  12R        TGCAGCCTGCAGAAAGCAGTG      21                       
  13F        CATGTCTGTTTCTCAAAGGGA      21        61            228
  13R        TCCTGAAAGCTCAACTGTTGTG     22                       

PCR conditions: 95 °C×7 min, 95 °C×30 s, Ta °C×30 s, 72 °C×30 s (45 cycles of step 2,3,4), 72 °C×10 min. MgCl~2~ concentration (mM) for PCR reaction of each exon: mM MgCl~2~: exon 2; 1.5 mM MgCl~2~: exon 1, 3, 4, 5FR, 6, 7, 8, 9, 10, 11, 12, 13; 2.0 mM MgCl~2~: exon 5AFAR.

Results
=======

A heterozygous nucleotide substitution at the splice donor site of intron 12 (IVS12+2T\>C) of *PAX6* was identified in the DNA samples from all three affected individuals. Screening for IVS12+2T\>C in 200 normal chromosomes using SSCP analysis revealed absence of this variant. The results of SSCP analysis in the shifted fragment (exon 12) and DNA sequence segment containing IVS12+2T\>C are shown in [Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}, respectively. This variant has been submitted to the [Human PAX6 Allelic Variant](http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6) database ([DB-ID PAX6_00580](http://lsdb.hgu.mrc.ac.uk/variants.php?select_db=PAX6&action=view&view=0001043%2C0000653%2C0)) \[[@r6]\].

![Results of SSCP analysis showing the aberrant migration of the amplification product of the mutant exon 12 in the three affected members (Lane 2, 3, and 4).](mv-v17-1305-f2){#f2}

![Sequencing results of Exon 12 in affected individuals showing the T→C change at donor splice site of intron 12 (IVS12+2 T\>C mutation).](mv-v17-1305-f3){#f3}

Discussion
==========

Aniridia is an autosomal dominant disorder resulting almost exclusively from mutations in the *PAX6* gene. It is familial in 70% cases and sporadic in others. Besides absence of iris tissue it encompasses several ocular abnormalities like glaucoma, corneal opacification, Reiger anomaly, optic nerve defects, CNS abnormalities, etc \[[@r1],[@r2],[@r5]\]. *PAX6* is an evolutionary conserved transcriptional regulator with expression in the iris tissue as well as other ocular tissues derived from neural crest cells. Its mutations are responsible for a variety of ocular phenotypes of varying severity \[[@r5],[@r8]\]. Mutations resulting in introduction of premature termination codons (PTCs) account for 77% aniridia patients, these arising by nonsense mutations, splice site mutations or insertion/deletions. The remaining mutations are missense or run-on mutations \[[@r5],[@r9]\]. The aniridia phenotype results from haploinsufficiency, which has been shown to arise in majority of cases by nonsense mediated decay of premRNA with premature termination codons (PTCs) \[[@r5],[@r9]\]. Mutations leading to milder phenotypes are usually missense with production of aberrant but functional protein \[[@r5],[@r9]\].

The mutation found in the family reported here is a novel substitution in donor splice site of Intron 12. The 10--13 exons of *PAX6* code for the PST domain, a region rich in proline, serine and threonine which functions as a transactivating domain that regulates the PAX6 protein homeodomain interaction with DNA \[[@r5],[@r8]\].

The RNA surveillance mechanism cannot detect PTC in the exon13 and last 50 bp of exon 12 \[[@r5],[@r10]\]. All mutations found in this region as well as splice site mutations in intron 12 are run-on mutations leading to haploinsufficiency of PAX6 by production of a protein with an elongated PST domain that interferes with homeodomain binding to DNA. Until date 6 variants in intron 12 have been found, 2 being non pathogenic and 4 associated with aniridia phenotype. One of these variants has been demonstrated to be associated with abnormally extended 3′ end of the protein, the other three not being characterized at the RNA level \[[@r6]\].

The splice site mutation found in this family is likely to be pathogenic by leading to aberrant splicing, but its effect on the RNA has not been established. We used the automated splice site analysis web interface to ascertain the effect of this mutation. The analyses predicted that the mutation would cause decrease in binding affinity of spliceosome proteins to this donor splice site, leading possibly to aberrant splicing \[[@r11]\]. This would probably lead to abolishing of the normal stop codon and abnormal 3′ elongation of the mRNA, which is the most common mechanism of pathogenicity of mutations in region distal to the 1,495th base pair of exon 12. Thus this is likely to be a pathogenic mutation in this family.

The phenotype of this family is similar to the aniridia cases where haploinsufficiency of PAX6 is the causative mechanism. However, an interesting finding is the presence of diffuse chorioretinal degeneration changes and vitreous involvement in the proband in this family. Hingorani et al. have reported the finding of Coats' disease like exudative vascular retinopathy in two of their patients who also had run-on mutations leading to an elongated PST domain. These two patients had frameshifting mutations in the exon 13 \[[@r12]\]. This raises the possibility that run-on mutations leading to an abnormal carboxy terminal extension of the PST domain may be associated with chorioretinal involvement in patients with aniridia.

To conclude, we report a novel splice site mutation in *PAX6* in a family with autosomal dominant aniridia. The finding of chorioretinal degeneration in association with this probable run-on mutation indicates the possibility of a genotype-phenotype correlation.
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